{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:55:18Z","timestamp":1793984118759,"version":"4.8.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02362-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:48:21Z","timestamp":1774342101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Acting RNA Interference Therapies for Cardiovascular Risk Reduction: Current Evidence and Emerging Targets"],"prefix":"10.1007","volume":"28","author":[{"given":"Kahtan","family":"Fadah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Elchouemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2362_CR1","doi-asserted-by":"publisher","unstructured":"Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et al. Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.\u00a0Circulation. 2025;151(8):e41\u2013660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303.\u00a0","DOI":"10.1161\/CIR.0000000000001303"},{"issue":"4","key":"2362_CR2","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","volume":"150","author":"DS Kazi","year":"2024","unstructured":"Kazi DS, Elkind MSV, Deutsch A, Dowd WN, Heidenreich P, Khavjou O, et al. Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a Presidential Advisory From the American Heart Association. Circulation. 2024;150(4):e89\u2013101. https:\/\/doi.org\/10.1161\/CIR.0000000000001258.","journal-title":"Circulation"},{"issue":"12","key":"2362_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jacc.2012.12.035","volume":"61","author":"MJ Budoff","year":"2013","unstructured":"Budoff MJ, Young R, Lopez VA, Kronmal RA, Nasir K, Blumenthal RS, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61(12):1231\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.12.035.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2362_CR4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jacc.2020.02.026","volume":"75","author":"B Lopez-Melgar","year":"2020","unstructured":"Lopez-Melgar B, Fernandez-Friera L, Oliva B, Garcia-Ruiz JM, Sanchez-Cabo F, Bueno H, et al. Short-term progression of multiterritorial subclinical atherosclerosis. J Am Coll Cardiol. 2020;75(14):1617\u201327. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.026.","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"2362_CR5","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"9","key":"2362_CR6","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1210\/jc.2019-01338","volume":"104","author":"JL Rosenzweig","year":"2019","unstructured":"Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(9):3939\u201385. https:\/\/doi.org\/10.1210\/jc.2019-01338.","journal-title":"J Clin Endocrinol Metab"},{"key":"2362_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/VHRM.S158641","volume":"14","author":"P Lansberg","year":"2018","unstructured":"Lansberg P, Lee A, Lee ZV, Subramaniam K, Setia S. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag. 2018;14:91\u2013102. https:\/\/doi.org\/10.2147\/VHRM.S158641.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"2362_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1253\/circj.CJ-20-1037","volume":"85","author":"AY Jang","year":"2021","unstructured":"Jang AY, Lim S, Jo SH, Han SH, Koh KK. New trends in dyslipidemia treatment. Circ J. 2021;85(6):759\u201368. https:\/\/doi.org\/10.1253\/circj.CJ-20-1037.","journal-title":"Circ J"},{"key":"2362_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044019","author":"O Ebenezer","year":"2023","unstructured":"Ebenezer O, Comoglio P, Wong GK, Tuszynski JA. Development of novel siRNA therapeutics: a review with a focus on Inclisiran for the treatment of hypercholesterolemia. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24044019.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2362_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","volume":"15","author":"BG Nordestgaard","year":"2018","unstructured":"Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjaerg-Hansen A. Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol. 2018;15(5):261\u201372. https:\/\/doi.org\/10.1038\/nrcardio.2018.3.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2362_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrm1644","volume":"6","author":"VN Kim","year":"2005","unstructured":"Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376\u201385. https:\/\/doi.org\/10.1038\/nrm1644.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2362_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0092-8674(00)81644-x","volume":"99","author":"H Tabara","year":"1999","unstructured":"Tabara H, Sarkissian M, Kelly WG, Fleenor J, Grishok A, Timmons L, et al. The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell. 1999;99(2):123\u201332. https:\/\/doi.org\/10.1016\/s0092-8674(00)81644-x.","journal-title":"Cell"},{"issue":"1","key":"2362_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","volume":"118","author":"H Zhang","year":"2004","unstructured":"Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell. 2004;118(1):57\u201368. https:\/\/doi.org\/10.1016\/j.cell.2004.06.017.","journal-title":"Cell"},{"issue":"6","key":"2362_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/s1097-2765(01)00418-x","volume":"8","author":"PD Zamore","year":"2001","unstructured":"Zamore PD. Thirty-three years later, a glimpse at the ribonuclease III active site. Mol Cell. 2001;8(6):1158\u201360. https:\/\/doi.org\/10.1016\/s1097-2765(01)00418-x.","journal-title":"Mol Cell"},{"issue":"30","key":"2362_CR15","doi-asserted-by":"publisher","first-page":"27595","DOI":"10.1074\/jbc.M504714200","volume":"280","author":"Y Zeng","year":"2005","unstructured":"Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J Biol Chem. 2005;280(30):27595\u2013603. https:\/\/doi.org\/10.1074\/jbc.M504714200.","journal-title":"J Biol Chem"},{"issue":"27","key":"2362_CR16","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.R900012200","volume":"284","author":"AJ Pratt","year":"2009","unstructured":"Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897\u2013901. https:\/\/doi.org\/10.1074\/jbc.R900012200.","journal-title":"J Biol Chem"},{"issue":"4","key":"2362_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nsmb918","volume":"12","author":"FV Rivas","year":"2005","unstructured":"Rivas FV, Tolia NH, Song JJ, Aragon JP, Liu J, Hannon GJ, et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol. 2005;12(4):340\u20139. https:\/\/doi.org\/10.1038\/nsmb918.","journal-title":"Nat Struct Mol Biol"},{"issue":"26","key":"2362_CR18","doi-asserted-by":"publisher","first-page":"15502","DOI":"10.1073\/pnas.95.26.15502","volume":"95","author":"MK Montgomery","year":"1998","unstructured":"Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998;95(26):15502\u20137. https:\/\/doi.org\/10.1073\/pnas.95.26.15502.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2362_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00779-x","volume":"6","author":"C Li","year":"2021","unstructured":"Li C, Ni YQ, Xu H, Xiang QY, Zhao Y, Zhan JK, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021;6(1):383. https:\/\/doi.org\/10.1038\/s41392-021-00779-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2362_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346. https:\/\/doi.org\/10.1038\/s41573-019-0017-4.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2362_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3724\/abbs.2024196","volume":"57","author":"X Feng","year":"2024","unstructured":"Feng X, Guang S. Functions and applications of RNA interference and small regulatory RNAs. Acta Biochim Biophys Sin (Shanghai). 2024;57(1):119\u201330. https:\/\/doi.org\/10.3724\/abbs.2024196.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"6989","key":"2362_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature02519","volume":"429","author":"JB Ma","year":"2004","unstructured":"Ma JB, Ye K, Patel DJ. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature. 2004;429(6989):318\u201322. https:\/\/doi.org\/10.1038\/nature02519.","journal-title":"Nature"},{"key":"2362_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235771","author":"F Foldes","year":"2020","unstructured":"Foldes F, Madai M, Papp H, Kemenesi G, Zana B, Geiger L, et al. Small interfering RNAs are highly effective inhibitors of Crimean-Congo hemorrhagic fever virus replication in vitro. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25235771.","journal-title":"Molecules"},{"issue":"5","key":"2362_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s0092-8674(02)00908-x","volume":"110","author":"J Martinez","year":"2002","unstructured":"Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110(5):563\u201374. https:\/\/doi.org\/10.1016\/s0092-8674(02)00908-x.","journal-title":"Cell"},{"issue":"2","key":"2362_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0092-8674(03)00759-1","volume":"115","author":"DS Schwarz","year":"2003","unstructured":"Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199\u2013208. https:\/\/doi.org\/10.1016\/s0092-8674(03)00759-1.","journal-title":"Cell"},{"issue":"11","key":"2362_CR26","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/nar\/gkg393","volume":"31","author":"F Czauderna","year":"2003","unstructured":"Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31(11):2705\u201316. https:\/\/doi.org\/10.1093\/nar\/gkg393.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2362_CR27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1261\/rna.25706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA \u201coff-target\u201d transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7):1179\u201387. https:\/\/doi.org\/10.1261\/rna.25706.","journal-title":"RNA"},{"issue":"7","key":"2362_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1261\/rna.30706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, et al. Position-specific chemical modification of siRNAs reduces \u201coff-target\u201d transcript silencing. RNA. 2006;12(7):1197\u2013205. https:\/\/doi.org\/10.1261\/rna.30706.","journal-title":"RNA"},{"key":"2362_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/nano7040077","author":"K Tatiparti","year":"2017","unstructured":"Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel). 2017. https:\/\/doi.org\/10.3390\/nano7040077.","journal-title":"Nanomaterials (Basel)"},{"key":"2362_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2015.10.015","volume":"98","author":"SW Young","year":"2016","unstructured":"Young SW, Stenzel M, Yang JL. Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol. 2016;98:159\u201369. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.015.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2362_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","volume":"61","author":"YK Oh","year":"2009","unstructured":"Oh YK, Park TG. SiRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850\u201362. https:\/\/doi.org\/10.1016\/j.addr.2009.04.018.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2362_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc800278e","volume":"20","author":"JH Jeong","year":"2009","unstructured":"Jeong JH, Mok H, Oh YK, Park TG. SiRNA conjugate delivery systems. Bioconjug Chem. 2009;20(1):5\u201314. https:\/\/doi.org\/10.1021\/bc800278e.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"2362_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492\u20137. https:\/\/doi.org\/10.1038\/nm.3847.","journal-title":"Nat Med"},{"key":"2362_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133\u201347. https:\/\/doi.org\/10.1016\/j.addr.2019.05.004.","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"2362_CR35","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1021\/bi00394a005","volume":"26","author":"RT Lee","year":"1987","unstructured":"Lee RT, Lee YC. Affinity labeling of the galactose\/N-acetylgalactosamine-specific receptor of rat hepatocytes: preferential labeling of one of the subunits. Biochemistry. 1987;26(20):6320\u20139. https:\/\/doi.org\/10.1021\/bi00394a005.","journal-title":"Biochemistry"},{"issue":"2","key":"2362_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1039\/d4md00652f","volume":"16","author":"F Ramirez-Cortes","year":"2025","unstructured":"Ramirez-Cortes F, Menova P. Hepatocyte targeting via the asialoglycoprotein receptor. RSC Med Chem. 2025;16(2):525\u201344. https:\/\/doi.org\/10.1039\/d4md00652f.","journal-title":"RSC Med Chem"},{"key":"2362_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","volume":"203","author":"AA D'Souza","year":"2015","unstructured":"D\u2019Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release. 2015;203:126\u201339. https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.022.","journal-title":"J Control Release"},{"issue":"25","key":"2362_CR38","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1021\/jacs.7b02694","volume":"139","author":"MK Schlegel","year":"2017","unstructured":"Schlegel MK, Foster DJ, Kel\u2019in AV, Zlatev I, Bisbe A, Jayaraman M, et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc. 2017;139(25):8537\u201346. https:\/\/doi.org\/10.1021\/jacs.7b02694.","journal-title":"J Am Chem Soc"},{"key":"2362_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17111408","author":"L Aranda-Lara","year":"2025","unstructured":"Aranda-Lara L, Escudero-Castellanos A, Trujillo-Nolasco M, Morales-Avila E, Ocampo-Garcia B, Oros-Pantoja R, et al. Small interfering RNA carriers for oncotherapy: a preclinical overview. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17111408.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2362_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1124\/jpet.122.001229","volume":"383","author":"L Sandra","year":"2022","unstructured":"Sandra L, T\u2019Jollyn H, Goeyvaerts N, Vermeulen A, Dosne AG, Perez-Ruixo JJ. Plasma and liver pharmacokinetics of the N-acetylgalactosamine short interfering RNA JNJ-73763989 in recombinant adeno-associated-hepatitis B virus-infected mice. J Pharmacol Exp Ther. 2022;383(1):70\u20139. https:\/\/doi.org\/10.1124\/jpet.122.001229.","journal-title":"J Pharmacol Exp Ther"},{"issue":"48","key":"2362_CR41","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","journal-title":"Eur Heart J"},{"key":"2362_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1260921","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol. 2023;14:1260921. https:\/\/doi.org\/10.3389\/fphar.2023.1260921.","journal-title":"Front Pharmacol"},{"key":"2362_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"W Alshaer","year":"2021","unstructured":"Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174178.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2362_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00549-3.","journal-title":"BioDrugs"},{"key":"2362_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-0716-1298-9_6","volume":"2282","author":"M Lu","year":"2021","unstructured":"Lu M, Zhang M, Hu B, Huang Y. siRNA design and GalNAc-empowered hepatic targeted delivery. Methods Mol Biol. 2021;2282:77\u2013100. https:\/\/doi.org\/10.1007\/978-1-0716-1298-9_6.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2362_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023;21(1):381. https:\/\/doi.org\/10.1186\/s12951-023-02147-z.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"2362_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01271-x","volume":"27","author":"F Di Giacomo-Barbagallo","year":"2025","unstructured":"Di Giacomo-Barbagallo F, Andreychuk N, Scicali R, Gonzalez-Lleo A, Piro S, Masana L, et al. Inclisiran, reasons for a novel agent in a crowded therapeutic field. Curr Atheroscler Rep. 2025;27(1):25. https:\/\/doi.org\/10.1007\/s11883-024-01271-x.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"2362_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395. https:\/\/doi.org\/10.1007\/s40265-021-01473-6.","journal-title":"Drugs"},{"issue":"16","key":"2362_CR49","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"issue":"16","key":"2362_CR50","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"2362_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2024.03.025","author":"RS Wright","year":"2024","unstructured":"Wright RS, Ray KK, Landmesser U, Koenig W, Raal FJ, Leiter LA, et al. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials. Mayo Clin Proc. 2024. https:\/\/doi.org\/10.1016\/j.mayocp.2024.03.025.","journal-title":"Mayo Clin Proc"},{"key":"2362_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.omtn.2023.03.020","volume":"32","author":"B Hu","year":"2023","unstructured":"Hu B, Huang Y. SiRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023;32:369\u201370. https:\/\/doi.org\/10.1016\/j.omtn.2023.03.020.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2362_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119822","author":"J Ena","year":"2025","unstructured":"Ena J, Fernandez-Riesgo M, Abellan R, Valls V. Effect of inclisiran on lipoprotein(a) values: a meta-analysis. Atherosclerosis. 2025. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119822.","journal-title":"Atherosclerosis"},{"issue":"2","key":"2362_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","volume":"4","author":"Y Huo","year":"2024","unstructured":"Huo Y, Lesogor A, Lee CW, Chiang CE, Mena-Madrazo J, Poh KK, et al. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18. JACC Asia. 2024;4(2):123\u201334. https:\/\/doi.org\/10.1016\/j.jacasi.2023.09.006.","journal-title":"JACC Asia"},{"issue":"11","key":"2362_CR55","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","volume":"24","author":"N Arnold","year":"2022","unstructured":"Arnold N, Koenig W. PCSK9 inhibitor wars: how does inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection. Curr Cardiol Rep. 2022;24(11):1657\u201367. https:\/\/doi.org\/10.1007\/s11886-022-01782-6.","journal-title":"Curr Cardiol Rep"},{"key":"2362_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/VHRM.S338424","volume":"19","author":"MS Albosta","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023;19:421\u201331. https:\/\/doi.org\/10.2147\/VHRM.S338424.","journal-title":"Vasc Health Risk Manag"},{"issue":"24","key":"2362_CR57","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","volume":"82","author":"RS Wright","year":"2023","unstructured":"Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, et al. Safety and tolerability of Inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82(24):2251\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.007.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2362_CR58","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325","volume":"2","author":"D Gaudet","year":"2023","unstructured":"Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023;2(12):EVIDoa2200325. https:\/\/doi.org\/10.1056\/EVIDoa2200325.","journal-title":"NEJM Evid"},{"issue":"1","key":"2362_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02929-9","volume":"24","author":"F Wang","year":"2025","unstructured":"Wang F, You D, Niu X, Shi J, Li Y, Qi L, et al. Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers. Cardiovasc Diabetol. 2025;24(1):399. https:\/\/doi.org\/10.1186\/s12933-025-02929-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2362_CR60","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"issue":"7","key":"2362_CR61","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2362_CR62","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med"},{"issue":"10","key":"2362_CR63","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2404147.","journal-title":"N Engl J Med"},{"key":"2362_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00290-6","author":"FJ Raal","year":"2025","unstructured":"Raal FJ, Bergeron J, Gaudet D, Rosenson RS, Sullivan DR, Turner T, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2025. https:\/\/doi.org\/10.1016\/S2213-8587(25)00290-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10459","key":"2362_CR65","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024;404(10459):1255\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4.","journal-title":"Lancet"},{"issue":"6","key":"2362_CR66","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","volume":"151","author":"A Greco","year":"2025","unstructured":"Greco A, Finocchiaro S, Spagnolo M, Faro DC, Mauro MS, Raffo C, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025;151(6):400\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069210.","journal-title":"Circulation"},{"issue":"3","key":"2362_CR67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/0115701611267835231210054909","volume":"22","author":"D Mukherjee","year":"2024","unstructured":"Mukherjee D, Nissen SE. Lipoprotein (a) as a biomarker for cardiovascular diseases and potential new therapies to mitigate risk. Curr Vasc Pharmacol. 2024;22(3):171\u20139. https:\/\/doi.org\/10.2174\/0115701611267835231210054909.","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"2362_CR68","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":"Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28(1):96\u2013103. https:\/\/doi.org\/10.1038\/s41591-021-01634-w.","journal-title":"Nat Med"},{"issue":"20","key":"2362_CR69","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"issue":"18","key":"2362_CR70","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA. 2024;331(18):1534\u201343. https:\/\/doi.org\/10.1001\/jama.2024.4504.","journal-title":"JAMA"},{"key":"2362_CR71","doi-asserted-by":"publisher","DOI":"10.2174\/011871529X390148250908045359","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Sharma K, Mukherjee D, Lepodisiran. Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a). Cardiovasc Hematol Disord Drug Targets. 2025. https:\/\/doi.org\/10.2174\/011871529X390148250908045359.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"23","key":"2362_CR72","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024;332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957.","journal-title":"JAMA"},{"issue":"21","key":"2362_CR73","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330(21):2075\u201383. https:\/\/doi.org\/10.1001\/jama.2023.21835.","journal-title":"JAMA"},{"issue":"17","key":"2362_CR74","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, et al. Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2415818.","journal-title":"N Engl J Med"},{"issue":"24","key":"2362_CR75","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/jama.2023.4570","volume":"329","author":"A Khvorova","year":"2023","unstructured":"Khvorova A. SiRNAs-a new class of medicines. JAMA. 2023;329(24):2185\u20136. https:\/\/doi.org\/10.1001\/jama.2023.4570.","journal-title":"JAMA"},{"key":"2362_CR76","unstructured":"Padda IS, Mahtani AU, Patel P, Parmar M. Small Interfering RNA (siRNA) Therapy. StatPearls. Treasure Island (FL) 2025."},{"issue":"6","key":"2362_CR77","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jmb.2013.11.024","volume":"426","author":"SN Lester","year":"2014","unstructured":"Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol. 2014;426(6):1246\u201364. https:\/\/doi.org\/10.1016\/j.jmb.2013.11.024.","journal-title":"J Mol Biol"},{"issue":"4","key":"2362_CR78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/mt.2010.4","volume":"18","author":"MP Gantier","year":"2010","unstructured":"Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW, et al. Rational design of immunostimulatory siRNAs. Mol Ther. 2010;18(4):785\u201395. https:\/\/doi.org\/10.1038\/mt.2010.4.","journal-title":"Mol Ther"},{"issue":"1","key":"2362_CR79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/intimm\/dxt040","volume":"26","author":"R Broering","year":"2014","unstructured":"Broering R, Real CI, John MJ, Jahn-Hofmann K, Ickenstein LM, Kleinehr K, et al. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int Immunol. 2014;26(1):35\u201346. https:\/\/doi.org\/10.1093\/intimm\/dxt040.","journal-title":"Int Immunol"},{"issue":"2","key":"2362_CR80","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/nar\/gku1343","volume":"43","author":"ST Sarvestani","year":"2015","unstructured":"Sarvestani ST, Stunden HJ, Behlke MA, Forster SC, McCoy CE, Tate MD, et al. Sequence-dependent off-target inhibition of TLR7\/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res. 2015;43(2):1177\u201388. https:\/\/doi.org\/10.1093\/nar\/gku1343.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2362_CR81","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nri3682","volume":"14","author":"S Carpenter","year":"2014","unstructured":"Carpenter S, Ricci EP, Mercier BC, Moore MJ, Fitzgerald KA. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol. 2014;14(6):361\u201376. https:\/\/doi.org\/10.1038\/nri3682.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2362_CR82","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nbt.1543","volume":"27","author":"AA Khan","year":"2009","unstructured":"Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 2009;27(6):549\u201355. https:\/\/doi.org\/10.1038\/nbt.1543.","journal-title":"Nat Biotechnol"},{"key":"2362_CR83","volume-title":"OXLUMO (lumasiran) injection, for subcutaneous use: Prescribing information","author":"US Food","year":"2020","unstructured":"Food US, Drug A. OXLUMO (lumasiran) injection, for subcutaneous use: Prescribing information. Silver Spring, MD: U.S. Food and Drug Administration; 2020."},{"key":"2362_CR84","volume-title":"GIVLAARI (givosiran) Injection: Product Monograph including Patient Medication Information","author":"BV Alnylam Netherlands","year":"2020","unstructured":"Alnylam Netherlands BV. GIVLAARI (givosiran) Injection: Product Monograph including Patient Medication Information. Health Canada Product Monograph: Health Canada; 2020."},{"key":"2362_CR85","volume-title":"RIVFLOZA (nedosiran) injection: Prescribing Information","author":"I Novo Nordisk","year":"2023","unstructured":"Novo Nordisk I. RIVFLOZA (nedosiran) injection: Prescribing Information. Full Prescribing Information: U.S. Food and Drug Administration; 2023."},{"key":"2362_CR86","volume-title":"ONPATTRO (patisiran) lipid complex injection: Prescribing Information","author":"I Alnylam Pharmaceuticals","year":"2018","unstructured":"Alnylam Pharmaceuticals I. ONPATTRO (patisiran) lipid complex injection: Prescribing Information. Full Prescribing Information: U.S. Food and Drug Administration; 2018."},{"key":"2362_CR87","unstructured":"Food US, Drug A. LEQVIO (inclisiran) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration. 2020."},{"key":"2362_CR88","unstructured":"Alnylam Netherlands BV. Amvuttra (vutrisiran) 25\u00a0mg solution for injection: EMA Product Information. Summary of Product Characteristics (SmPC). European Medicines Agency; 2022."},{"issue":"12","key":"2362_CR89","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/j.1525-1497.2006.00591.x","volume":"21","author":"JA Gazmararian","year":"2006","unstructured":"Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med. 2006;21(12):1215\u201321. https:\/\/doi.org\/10.1111\/j.1525-1497.2006.00591.x.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"2362_CR90","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.3307","volume":"6","author":"ET Roberts","year":"2025","unstructured":"Roberts ET, Figueroa JF. Mitigating the dangers of Medicaid churn among dual-eligible beneficiaries. JAMA Health Forum. 2025;6(9):e253307. https:\/\/doi.org\/10.1001\/jamahealthforum.2025.3307.","journal-title":"JAMA Health Forum"},{"issue":"9","key":"2362_CR91","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6(9):1060\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2362_CR92","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cjco.2025.01.013","volume":"7","author":"P Gouda","year":"2025","unstructured":"Gouda P, Ezekowitz JA, Gay A, Vogtlander K, Aboyans V, Debus S, et al. Dual pathway inhibition in patients with atherosclerosis with or without heart failure: insights from the XATOA registry. CJC Open. 2025;7(4):473\u201380. https:\/\/doi.org\/10.1016\/j.cjco.2025.01.013.","journal-title":"CJC Open"},{"issue":"2\u20133","key":"2362_CR93","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard L, Rossi JJ. Rnai therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2\u20133):75\u201386. https:\/\/doi.org\/10.1016\/j.addr.2007.03.005.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"2362_CR94","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/HCO.0000000000000972","volume":"37","author":"S Kettunen","year":"2022","unstructured":"Kettunen S, Ruotsalainen AK, Yla-Herttuala S. Rna interference-based therapies for the control of atherosclerosis risk factors. Curr Opin Cardiol. 2022;37(4):364\u201371. https:\/\/doi.org\/10.1097\/HCO.0000000000000972.","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"2362_CR95","doi-asserted-by":"publisher","first-page":"961","DOI":"10.18553\/jmcp.2021.27.7.961","volume":"27","author":"F Agboola","year":"2021","unstructured":"Agboola F, Lin GA, Kazi DS, McKenna A, Pearson SD. The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD. J Manag Care Spec Pharm. 2021;27(7):961\u20136. https:\/\/doi.org\/10.18553\/jmcp.2021.27.7.961.","journal-title":"J Manag Care Spec Pharm"},{"key":"2362_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12020058","author":"I Sehgal","year":"2024","unstructured":"Sehgal I, Eells K, Hudson I. A comparison of currently approved small interfering RNA (siRNA) medications to alternative treatments by costs, indications, and Medicaid coverage. Pharmacy (Basel). 2024. https:\/\/doi.org\/10.3390\/pharmacy12020058.","journal-title":"Pharmacy (Basel)"},{"issue":"4","key":"2362_CR97","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/HCO.0000000000000977","volume":"37","author":"D Mukherjee","year":"2022","unstructured":"Mukherjee D, Mikhailidis DP. Editorial: the year in lipids and emerging risk factors. Curr Opin Cardiol. 2022;37(4):334. https:\/\/doi.org\/10.1097\/HCO.0000000000000977.","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"2362_CR98","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jacl.2025.05.003","volume":"19","author":"WAM Schonck","year":"2025","unstructured":"Schonck WAM, Mulder J, Tromp TR, Reeskamp LF, Hovingh GK, van Lennep JER, et al. Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - a physician survey. J Clin Lipidol. 2025;19(4):1009\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2025.05.003.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2362_CR99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14740338.2023.2293201","volume":"23","author":"S Dutta","year":"2024","unstructured":"Dutta S, Shah R, Singhal S, Singh S, Piparva K, Katoch CDS. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients. Expert Opin Drug Saf. 2024;23(2):187\u201398. https:\/\/doi.org\/10.1080\/14740338.2023.2293201.","journal-title":"Expert Opin Drug Saf"},{"issue":"17","key":"2362_CR100","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327(17):1679\u201387. https:\/\/doi.org\/10.1001\/jama.2022.5050.","journal-title":"JAMA"},{"issue":"16","key":"2362_CR101","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2025.0031","volume":"333","author":"Y Wu","year":"2025","unstructured":"Wu Y, Meng J, Gao S. Zerlasiran for the treatment of atherosclerotic cardiovascular disease. JAMA. 2025;333(16):1456\u20137. https:\/\/doi.org\/10.1001\/jama.2025.0031.","journal-title":"JAMA"},{"key":"2362_CR102","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA\/ACC\/AACVPR\/AAPA\/ABC, PCNA Guideline on the Management of Blood Cholesterol.\u00a0\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/\u00a0A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","DOI":"10.1161\/CIR.0000000000000625"},{"issue":"20","key":"2362_CR103","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An \u201cInclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.382.","journal-title":"J Am Coll Cardiol"},{"key":"2362_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2859","author":"H Luo","year":"2024","unstructured":"Luo H, Zheng S, Cao H, Singh A, Tong C, Zhang H, et al. Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.2859.","journal-title":"Eur Heart J"},{"key":"2362_CR105","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","volume":"374","author":"F Kronenberg","year":"2023","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107\u201320. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.012.","journal-title":"Atherosclerosis"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02362-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:48:24Z","timestamp":1774342104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02362-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2362"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02362-8","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"39"}}